Gocovri
Named-patient access overview. Gocovri is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Gocovri (amantadine extended-release capsules) is an oral, once-daily bedtime-dosed extended-release amantadine developed approximately by Adamas Pharmaceuticals and subsequently held by Supernus Pharmaceuticals, with US FDA approval in 2017 for treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, and an expanded indication in 2021 for off episodes adjunctive to levodopa.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Gocovri
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Gocovri is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Gocovri in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Gocovri
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.